Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights some of the controversies in characterizing and distinguishing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Stein explains that whilst high-risk MDS and low-blast count AML are very similar, it is important to look for co-occurring molecular alterations in patients with HR-MDS compared to patients with AML when selecting a therapy. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.